Using the CDK4/6 inhibitorribociclib as a prototype, we identified a covalent handle that, whenappended to the exit vector of ribociclib, induced the proteasome-mediateddegradation of CDK4 in cancer cells. The gene discussed is CDK4; the disease is cancer.